Clinical Trials on Human Immunodeficiency Virus in Australia

Total 893 results

Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
GlaxoSmithKline

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs

Hepatitis B

Belgium, Ukraine, Australia
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Hepatitis C

France, Australia
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
Viravaxx AG
Gouya Insights; KKS MedUni Vienna

Recruiting

Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001

Hepatitis B

Austria
DiaSorin Molecular LLC

Completed

LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia

Coronavirus Disease 2019 | Influenza A | Influenza Type B

Australia
Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Kirby Institute

Terminated

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs (DARLO-C)

Hepatitis C

Australia
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
Kirby Institute
University of Public Health, Myanmar

Completed

Simplified Monitoring Myanmar SM2 Study (SM2)

HIV Infections | Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Ology Bioservices

Completed

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Influenza

Austria, Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
St Vincent's Hospital Melbourne
Merck Sharp & Dohme LLC

Unknown

A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (HCV-6)

Chronic Hepatitis C

Australia
Macfarlane Burnet Institute for Medical Research...
St Vincent's Hospital Melbourne

Unknown

The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach (TAP)

Hepatitis C | Drug Abuse, Intravenous

Australia
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005

Influenza

Austria, Germany
Kirby Institute

Recruiting

The National Australian HCV Point-of-Care Testing Program - Minimal Dataset

Hepatitis C

Australia
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States, United Kingdom, France, Spain, Germany, Belgium, Puerto Rico, Canada, Italy, Austria, Australia, Portugal
Monash University
The Alfred; University of Melbourne

Recruiting

Human Papillomavirus in Young People Epidemiological Research 3 (HYPER3)

Cancer | Anal Cancer | HPV Infection | HPV | Human Papillomavirus Infection | Men | HPV 16 Infection

Australia
Monash University
The Alfred; University of Melbourne

Recruiting

Human Papillomavirus in Young People Epidemiological Research 4 (HYPER4)

Cancer | Anal Cancer | HPV Infection | HPV | Human Papillomavirus Infection | Men | HPV 16 Infection

Australia
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Adults

Influenza | Pandemic Influenza

Austria, Germany
Kirby Institute
National Health and Medical Research Council, Australia

Recruiting

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (ETHOS II)

Hepatitis C

Australia
Macfarlane Burnet Institute for Medical Research...
St Vincent's Hospital Melbourne

Completed

The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital

Hepatitis C

Australia, New Zealand
Hoffmann-La Roche

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Hepatitis C, Chronic

New Zealand, Australia
Ark Biosciences Inc.

Terminated

A Study of AK0529 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

Australia
Kirby Institute
Gilead Sciences; The University of New South Wales

Completed

Tenofovir in HIV/HBV Coinfection (TICO)

HIV Infection | Hepatitis B Coinfection

Australia, Thailand
Kirby Institute
AbbVie

Completed

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (TARGET3D)

Hepatitis C, Acute

United Kingdom, Australia, New Zealand
Clover Biopharmaceuticals AUS Pty Ltd

Recruiting

First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

Respiratory Syncytial Virus Infection

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Medical University of Vienna

Completed

Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders (NRSily)

Hepatitis C

Austria
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Hepatitis C

Austria
Assembly Biosciences

Completed

Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Taiwan, Australia, Hong Kong, United Kingdom
Medical University of Graz

Completed

Quantification of Side Effects During Hepatitis C Therapy

Hepatitis C

Austria
Kirby Institute

Active, not recruiting

Control and Elimination Within Australia of Hepatitis C From People Living With HIV (CEASE)

Hepatitis C | HIV | HIV-HCV Coinfection

Australia
Leiden University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Horizon...

Recruiting

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID (RAG1-SCID)

Severe Combined Immunodeficiency Due to RAG1 Deficiency

Spain, Netherlands, Italy, Poland, Australia, Turkey, United Kingdom
GlaxoSmithKline

Completed

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

Virus Diseases

United States, South Africa, Australia
Macfarlane Burnet Institute for Medical Research...
The Alfred

Completed

Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals (co-EC)

Hepatitis C | HIV

Australia
Prof. Dr. Alice Schmidt

Unknown

Hepatitis C in Renal Transplant Recipients

Renal Transplantation | Chronic Hepatitis C-virus Infection

Austria
Medical University of Vienna

Completed

Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) (AURIC)

Cirrhosis | Chronic Hepatitis C

Austria
Ology Bioservices

Completed

Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults

Influenza | Avian Influenza

Austria, Finland
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (COVID-19)

COVID-19 | Influenza

Australia, New Zealand
Hoffmann-La Roche

Completed

Influenza Resistance Information Study (IRIS)

Influenza

Australia, Hong Kong, United States, France, Germany, Netherlands, Norway, Poland
Bristol-Myers Squibb

Completed

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Hepatitis C Virus

Australia, United States, Canada, France, Denmark, Italy

3

Subscribe